Hence, BPC-157 is clearly on the do not compound for human use list
Rabarison KM, Bouldin ED, Bish CL, McGuire LC, Taylor CA, Greenlund KJ
The primary risks are associated with the known side effects of HGH and the potential for using impure or contaminated peptides
These peptides are discussed in tendon and tissue repair communities, but patients should not treat them as guaranteed tendon-healing treatments
BPC-157 and TB-500 Dosage Protocol BPC-157: 250500mcg daily, injected subcutaneously near the injury site TB-500: 22.5mg twice weekly (loading phase) for 46 weeks, then 2mg once weekly (maintenance phase) The combination is typically used for 612 weeks, depending on injury severity and healing progress
However, symptoms should greatly improve or be alleviated with the continued use of supplements